New prognostic factors identified for testicular seminoma relapse
September 29th 2023About 1 of every 5 patients with stage I seminoma relapses; however, “the level of evidence supporting the use of currently defined risk factors in decision making is low,” wrote lead author Thomas Wagner, MD, and coinvestigators.
Adding SBRT to frontline abiraterone shows benefit in oligometastatic CRPC
September 25th 2023The addition of SBRT to upfront abiraterone acetate and prednisone (AAP) reduced the risk of disease progression or death by 65% compared with AAP alone in patients with oligometastatic castration-resistant prostate cancer.
Enfortumab vedotin plus pembrolizumab improves survival in frontline urothelial cancer
September 22nd 2023The EV-302 trial is the confirmatory trial for the FDA’s accelerated approval of pembrolizumab plus enfortumab vedotin for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.
Preliminary results promising for 64Cu SAR-Bombesin in prostate cancer
September 14th 2023“We are pleased with the results we have generated in the BOP trial, which have shown that 64Cu SAR-Bombesin can detect lesions in men with biochemically recurrent prostate cancer that are negative or equivocal on PSMA PET,” said Louise Emmett, MBChB, FRACP, MD.
Guidelines published for 177Lu-PSMA-617 patient selection and use in prostate cancer
September 6th 2023The Society of Nuclear Medicine and Molecular Imaging announced a consensus statement on patient selection and appropriate use of the radionuclide therapy 177Lu-PSMA-617 in patients with prostate cancer.
Olaparib/abiraterone regimen approved in Japan for BRCA-positive mCRPC
August 24th 2023The approval of the olaparib/abiraterone regimen was based on an exploratory subgroup analysis of the phase 3 PROpel trial consisting of the 85 patients in the study with BRCA-positive metastatic castration-resistant prostate cancer.
UGN-102 improves on current standard in low-grade intermediate-risk NMIBC
August 8th 2023The mitomycin-containing reverse thermal gel UGN-102 with or without TURBT reduced the risk of recurrence, progression, or death vs TURBT alone in patients with low-grade intermediate-risk non-muscle invasive bladder cancer.